World Clinical Trials Day 2024: Pfizer’s Commitment to Improving the Clinical Trial Experience

Tomorrow’s breakthroughs start today, with clinical trials. May 20^th marks World Clinical Trials Day, celebrated to recognize the people who make clinical research possible and express appreciation for the vital research taking place across the world to help improve healthcare. This day commemorates the first clinical trial conducted by James Lind in 1747, which was a pivotal moment that paved the way for modern clinical research.

Researchers at Pfizer relentlessly pursue potential breakthroughs to help change the lives of patients around the world. The company significantly invests in clinical trials, research and development, as well as research partnerships to bring forward the medicines and vaccines of the future.

Providing Individual Participant Data At Scale

Every clinical trial is built on trust, and transparency is foundational to building trust.

As part of Pfizer’s efforts toward greater transparency and building trust, the company has made a commitment to return certain individual data to its clinical trials participants through its Participant Data Return initiative. Returning individual participant data is a critical step toward improving the clinical trial experience, building trust with participants, and advancing health information equity.

“Patients are at the heart of what we do,” said David Leventhal, Senior Director, Data Sharing & Disclosure Lead at Pfizer. “By giving participants back certain of their clinical trial data, we can help them to provide their healthcare provider with additional information about their health.”

Access to clinical trial data empowers participants with information and resources to manage their health and wellness. Pfizer is the first in the industry to return individual clinical trial results to clinical trial participants in the U.S. at scale in a meaningful, contextualized way through this initiative. At least 12 months post completion of the Pfizer-sponsored clinical trial, participants have the option to access certain individual data and can share it with their healthcare provider. Pfizer is continuing to explore a variety of options to expand this capability globally.

The Individual Participant Data Return initiative is just one more step in the company’s continued journey to improve the patient experience through the transparent return of participant data.

Innovative Ways to Connect and Contribute to Clinical Research

In 2023, Pfizer also launched PfizerLink.com, the first industry-sponsored research registry, which aims to make it easier for interested individuals to find Pfizer clinical trials, helping to address some of the longstanding challenges associated with clinical trial recruitment, and advances Pfizer’s mission of bringing medicines to patients faster.

This novel approach allows interested individuals—either healthy volunteers or those with medical conditions—to share information about themselves to potentially be matched to an available Pfizer clinical trial with the help of a PfizerLink Navigator.

By joining PfizerLink, registry participants also have the opportunity to potentially help contribute to the advancement of medical research for themselves and for their communities.

Shaping the Future of Clinical Trials

Pfizer’s work in clinical trials is fundamental to achieving its purpose of delivering breakthroughs that change patients’ lives. The company strives to maintain the highest ethical, scientific, and clinical standards in all its clinical research around the world.

Aligned with Pfizer’s core value of Equity, the company continues to find new ways to remove barriers to clinical trial participation and improve the experience of clinical trial participants, such as using digital tools, local healthcare providers and settings, and other approaches to make clinical trials more flexible and accessible.

Pfizer’s innovative medical research wouldn’t be possible without the people that participate in clinical trials each year, and the company is grateful for their invaluable contributions.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at www.pfizer.com and the SEC’s website at www.sec.gov.